Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
R-Pharm
Icahn School of Medicine at Mount Sinai
Fondazione del Piemonte per l'Oncologia
University of California, San Diego
Nanfang Hospital, Southern Medical University
Martin-Luther-Universität Halle-Wittenberg
ChineseAMS
ChineseAMS